Literature DB >> 6253402

Relationship of in vitro immune responses to Epstein-Barr herpesvirus and severity of infectious mononucleosis.

K Goldstein, P K Lai, M Lightfoote, A P Andrese, D Fuccillo, R J Connor, P H Levine.   

Abstract

Immune responses to Epstein-Barr herpesvirus (EBV) and EBV-related antigens were studied serially in 18 patients with heterophil antibody-positive infectious mononucleosis and in 18 control subjects. Enhanced cellular immune responses to EBV particles and to EBV intracellular soluble antigens were found in the patients at convalescence, suggesting that the development of specific cellular immune responses was associated with apparent control of the virus infection. In addition, a correlation between severity of disease and specific cellular immune response was found. Patients with severe clinical signs were found to have a more active cellular immune response to EBV intracellular soluble antigens early in the infection compared with patients with mild disease. This suggests that an increased immune reactivity to intracellular antigens during the early part of the illness is related to the severity of clinical manifestations in infectious mononucleosis. Serum antibody to viral capsid antigen and early antigen was not related to the severity of clinical disease.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6253402      PMCID: PMC551222          DOI: 10.1128/iai.29.3.945-952.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Prevalence, incidence and persistence of EB virus antibody in young adults.

Authors:  J C Niederman; A S Evans; L Subrahmanyan; R W McCollum
Journal:  N Engl J Med       Date:  1970-02-12       Impact factor: 91.245

2.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

3.  Thymic aplasia with lymphopenia, plasma cells, and normal immunoglobulins. Relation to measles virus infection.

Authors:  A J Nahmias; D Griffith; C Salsbury; K Yoshida
Journal:  JAMA       Date:  1967-09-04       Impact factor: 56.272

Review 4.  Effects of anti-lymphoid sera on viral infections.

Authors:  M S Hirsch; F A Murphy
Journal:  Lancet       Date:  1968-07-06       Impact factor: 79.321

5.  Newborn infection with Herpesvirus hominis types 1 and 2.

Authors:  A J Nahmias; W R Dowdle; W E Josey; Z M Naib; L M Painter; C Luce
Journal:  J Pediatr       Date:  1969-12       Impact factor: 4.406

Review 6.  A leucocyte migration technique for in vitro detection of cellular (delayed type) hypersensitivity in man.

Authors:  G Bendixen; M Soborg
Journal:  Dan Med Bull       Date:  1969-01

7.  Seroepidemiologic studies of infectious mononucleosis with EB virus.

Authors:  A S Evans; J C Niederman; R W McCollum
Journal:  N Engl J Med       Date:  1968-11-21       Impact factor: 91.245

8.  Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis.

Authors:  G Henle; W Henle; V Diehl
Journal:  Proc Natl Acad Sci U S A       Date:  1968-01       Impact factor: 11.205

9.  A colony inhibition (CI) technique for demonstration of tumor cell destruction by lymphoid cells in vitro.

Authors:  I Hellström
Journal:  Int J Cancer       Date:  1967-01-15       Impact factor: 7.396

10.  EB virus antibody at different ages.

Authors:  M S Pereira; J M Blake; A D Macrae
Journal:  Br Med J       Date:  1969-11-29
View more
  2 in total

1.  Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.

Authors:  Wei Bu; Gregory M Hayes; Hui Liu; Lorraine Gemmell; David O Schmeling; Pierce Radecki; Fiona Aguilar; Peter D Burbelo; Jennifer Woo; Henry H Balfour; Jeffrey I Cohen
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

2.  Infectious mononucleosis complicated by acute hepatitis and myocarditis: a response to corticosteroids.

Authors:  Robin Ghosal; Keir E Lewis; Sriram Chandramouli
Journal:  BMJ Case Rep       Date:  2009-04-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.